Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder
Addiction is a complex mental and behavioral disorder that changes the neurochemistry and physiology of the brain. Genetics also plays a significant role in the pathophysiology of addiction. Butyrylcholinesterase (BChE), a cholinergic enzyme, has been implicated in the metabolism of various drugs, including cocaine, and an association between single-nucleotide polymorphisms (SNPs) of the butyrylcholinesterase gene (BCHE) and neuronal disorders has been reported. We report here the first investigation to be conducted on the status of BChE activity and the potential association of two BCHE gene SNPs, rs3495 (c.*189G > A) and rs1803274 (c.1699G>A, p.Ala567Thr, K-variant), with addiction vulnerability in heroin, hashish and polydrug users. Seventy-five individuals with an addiction to heroin, hashish and/or polydrug use were recruited to this study. BChE levels in the plasma were determined by Ellman’s principle. SNPs were genotyped by standard procedures, followed by Sanger sequencing. Plasma BChE levels were found to be significantly higher (p ≤ 0.05) in addicts (mean ± standard error of the mean 0.031 ± 0.004 μmol/L/min; 95% confidence interval [CI] 0.024–0.038) than in non-addicts (controls) (0.014 ± 0.001 μmol/L/min; 95% CI 0.012–0.017). Statistical significant differences were also observed between the addicted cohorts. A statistically significant association for both SNPs (rs3495 and rs1803274) was not observed in addicted subjects tested in the dominant, recessive and allele genetic models, but trends of variations of the rs3495 risk G allele were noted. The authors conclude that BChE plays significant roles in addiction pathophysiology as increased BChE activity in blood samples obtained from the cohorts with addiction was evident. Further studies in this direction may provide novel approaches for the treatment of addiction, but studies with a larger sample size and different ethnic groups are warranted for broader conclusions to be drawn.
KeywordsSubstance abuse Butyrylcholinesterase rs3495 rs1803274 Hashish Polydrug
The authors acknowledge Mental Health and Care, Islamabad and Sehar Rehabilitation Center, Sargodha for facilitating the research.
The work was sponsored by CIIT research grant #16–20/CRGP/CIIT/IBD/16 to Dr. Syed M Nurulain.
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
Conflict of Interest
The authors declare no conflicts of interest and no financial interests.
- Aeinehband S, Lindblom RPF, Al Nimer F, Vijayaraghavan S, Sandholm K, Khademi M, Olsson T, Nilsson B, Ekdahl KN, Darreh-Shori T, Piehl F (2015) Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One 10:e0122048CrossRefGoogle Scholar
- Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50:1086–1103PubMedPubMedCentralGoogle Scholar
- Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR, Medland SE, Henders AK, Heath AC, Madden PAF, Visscher PM, O’Connor DT, Montgomery GW, Martin NG, Whitfield JB (2011) GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Hum Mol Genet 20:4504–4514CrossRefGoogle Scholar
- Bono GF, Simão-Silva DP, Batistela MS, Josviak ND, Dias PFR, Nascimento GA, Souza RLR, Piovezan MR, Souza RKM, Furtado-Alle L (2015) Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer’s disease in a southern Brazilian population. Neurochem Int 81:57–62CrossRefGoogle Scholar
- Cokugras AN (2003) Butyrylcholinesterase: structure and physiological importance. Turk J Biochem 28:54–61Google Scholar
- Guimarães LO, de Andrade FA, Bono GF, Setoguchi TE, Brandão MB, Chautard-Freire-Maia EA, dos Santos ICR, Picheth G, Faria AC, Réa RR, Souza RLR, Furtado-Alle L (2014) Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids. Genet Mol Biol 37:1–6CrossRefGoogle Scholar
- Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M (2013) A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 15(2). https://doi.org/10.4088/PCC.12r01412
- Shields KA, Lewis J (2018) The identification of butyrycholinesterase (BCHE) polymorphisms in a small Australian Defence force cohort. http://www.dsto.defence.gov.au/corporate/reports/DSTO-TR-2503.pdf. Accessed 28 July 2018
- UNODC (United Nations Office on Drugs and Crime) (2013) Drugs use in Pakistan. https://www.unodc.org/documents/pakistan/Survey_Report_Final_2013.pdf. Accessed 28 July 2018
- UNODC (United Nations Office on Drugs and Crime) (2016) World drug report 2016—world. https://reliefweb.int/report/world/unodc-world-drug-report-2016. Accessed 28 July 2018
- Wang J-C, Kapoor M, Goate AM (2012) The genetics of substance dependence. Annu Rev Genomics Hum Genet 13:241–261. https://doi.org/10.1146/annurev-genom-090711-163844 CrossRefPubMedPubMedCentralGoogle Scholar
- Zaman M, Razzaq S, Hassan R, Qureshi J, Ijaz H, Hanif M, Rahman Chughtai F (2015) Drug abuse among the students. Pakistan J Pharmaceutical Res 1(1)41–47Google Scholar